Biodesix awarded advanced diagnostic laboratory test status for its nodify cdt® test by the center for medicare and medicaid services

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the centers for medicare & medicaid services (cms) has designated the nodify cdt® test as an advanced diagnostic laboratory test (adlt) effective june 30, 2023. obtaining adlt status is a recognition that the nodify cdt test meets the stringent criteria established under the protecting access to medicare act of 2014 (pama). adl.
BDSX Ratings Summary
BDSX Quant Ranking